Codexis, Inc. has achieved a significant development milestone under a research agreement with Schering-Plough to rapidly generate a novel biocatalytic process to produce a key intermediate for an undisclosed human therapeutics compound. This program is based on Codexis’ MolecularBreeding pharmaceutical process re-engineering platform, and is expected to reduce manufacturing costs and environmental waste in the final production process. “The agreement with Schering-Plough was ann...